Manufacturing discipline for translational science
Medical devices and biologics — from first GMP build to commercial readiness
RedRock exists for the moment translational science has to reach patients - reproducible dose/response at clinical scale that will carry through to commercial production. Manufacturing strategy is how a breakthrough survives the regulatory and financial transition to commercial production. We build the manufacturing discipline that treats sterility and function as a single problem, protecting both the science and the momentum behind it.
WHAT THAT MEANS IN PRACTICE
Contamination control and sterility assurance
In devices, sterility is a pass/fail gate ahead of function. In biologics, it's one specification among many. Programs fail in the space between those two assumptions. Doctoral work in implant infection and biofilm, applied to bioreactor decontamination, environmental monitoring, and sterilization operations.
Facility, utility, and equipment reliability
HVAC and controlled environments, SCADA and monitoring, cryogenic and gas systems, backup power, alarm strategy. The unglamorous infrastructure that quietly decides whether a batch survives.
Operational systems and metrics
Schedule attainment, load leveling, KPI design, and the process mapping underneath them. Lean Six Sigma Black Belt, built on Toyota-method consulting foundations.
Capital and regulatory sequencing
Knowing when to spend aggressively to protect a clinical timeline and when strategic patience is the better discipline — and being able to defend either to a board.
PROOF
5× increase in deviation-free yields. A complex eight-week aseptic bioprocess was failing, and the new 3D culture launch took the blame. System-level analysis found the real constraint downstream in media and buffer preparation. Pivotal trial completed on time, no added headcount, no capital spend.
2.5-year plan compressed to 6 months. A vascular tissue engineering startup faced a two-and-a-half-year path to first-in-man-enabling data. Rebuilding the sequence — running large-animal work out of an available facility during COVID, and converting the lab to GMP in parallel rather than serially — delivered the data in six months.
50% throughput increase with 20% fewer staff. Replacing reactive dispatch with a fixed schedule made manpower plannable. When the contract overflow sterilizer went down for eight weeks, 100% of the load ran internally with zero interruption.
Recent Projects:
